Adicet Bio Inc(ACET) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -11.53 | Insider Own | 12.22% | Shs Outstand | 9.4M | Perf Week | -13.02% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 36.47% | Insider Trans | - | Shs Float | 8.2M | Perf Month | -56.32% |
| Enterprise Value | -0.07B | PEG | - | EPS next Q | -1.58 | Inst Own | 53.37% | Short Float | 5.91% | Perf Quarter | -51.95% |
| Income | -0.10B | P/S | - | EPS this Y | 62.49% | Inst Trans | 0.89% | Short Ratio | 2.56 | Perf Half Y | -50.32% |
| Sales | 0.00B | P/B | 0.31 | EPS next 5Y | 63.23% | ROA | -63.62% | Short Interest | 0.49M | Perf YTD | -53.21% |
| Book/sh | 12.83 | P/C | 0.31 | EPS past 3/5Y | 14.57% 26.71% | ROE | -78.08% | 52W High | -73.7% ($14.98) | Perf Year | -72.33% |
| Cash/sh | 12.63 | P/FCF | - | Sales past 3/5Y | - | ROIC | -76.04% | 52W Low | -0.51% ($3.96) | Perf 3Y | -80.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 44.73% | Gross Margin | - | Volatility(W/M) | 7.71% 9.15% | Perf 5Y | -97% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.71 | EPS Q/Q | 63.75% | Profit Margin | - | RSI (14) | 21.74 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.71 | Sales Q/Q | - | SMA20 | -27.27% ($5.42) | Beta | 1.66 | Target Price | $34.83 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/8/5 | SMA50 | -48.07% ($7.59) | Rel Volume | 0.86 | Prev Close | $3.99 |
| Employees | 102 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | -17.61% - | SMA200 | -49.36% ($7.78) | Avg Volume(3M) | 0.19M | Price | $3.94 |
| IPO | 2018/1/26 | Option/Short | Yes/Yes | Trades | 1977 | Volume | 162,826 | Change | -1.25% |
A US clinical-stage biotech company developing allogeneic immune cell therapies using gamma delta T cells. Founded in 2014 and headquartered in the US, it is researching chimeric antigen receptor (CAR) cell therapy candidates in the oncology and autoimmune disease fields.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
ACET has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +62.5% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 53.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #439 of 594 in the industry
Based on market cap of $37M.
GRCE#435 Grace Therapeutics Inc $38M PER - 
TIL#436 Instil Bio Inc $38M PER - 
DWTX#437 Dogwood Therapeutics Inc $38M PER - 
VERU#438 Veru Inc $38M PER - ACET#439 Adicet Bio Inc $37M PER - 
FAQ
What kind of company is ACET?
ACET belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACET?
The market cap of ACET is approximately $37M, ranking 4,984 within its sector.
What is the 52-week high and low for ACET?
ACET has recorded a 52-week high of $14.98 and a low of $3.96.
